Latest News
- Diversifying the Supply of Raw Materials
- Noramco Announces Strategic Alignment with Purisys and Halo Pharma, Launching the Noramco Group as an Integrated North American-Based API and Drug Product Supply Chain Services Provider
- Noramco Announces the Acquisition of the Cambrex Drug Product Business Unit
- Noramco Announces Submission and Reactivation of the Drug Master File for Active Pharmaceutical Ingredient Methylnaltrexone Bromide
- Noramco Celebrates Diversity and International Women’s Day
- Noramco Announces Submission of Drug Master File for Lisdexamfetamine Dimesylate ─ Active Pharmaceutical Ingredient
- Meet us at DCAT Week
- Noramco Cannabinoids Business to Become Purisys
- Noramco at iCDP
- Say Hello to Amber Burch
- Say Hello to Gregory Moore
- Noramco Presents Comments and Answers Questions at FDA Hearing on Cannabidiol
- Nemus Bioscience Signs Agreement with Noramco
- Noramco Adds Capacity and Dual Sources of Supply for Cannabinoids
- Noramco Announces Provisional Patent Application of Proprietary Cannabidiol (CBD)
{"effect":"fade","fontstyle":"normal","autoplay":"true","timer":"6000"}